Barinthus Biotherapeutics (BRNS)
NASDAQ: BRNS
· Real-Time Price · USD
1.26
0.02 (1.61%)
At close: Aug 18, 2025, 10:57 AM
Barinthus Biotherapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -19.66M | -20.35M | -2.66M | -16.95M | -15.48M | -17.29M | -14.11M | -23.82M | -18.22M | -21.16M | 8.22M | 15.69M | 2.57M | -15.17M | -4.57M | -15.98M | -15.39M |
Depreciation & Amortization | 2.03M | 1.43M | 1.48M | 1.47M | 1.43M | 1.44M | 1.47M | 1.3M | 1.22M | 1.18M | 1.19M | 992K | 966K | 321K | 85K | 104K | 92K |
Stock-Based Compensation | 468K | 755K | 1.91M | 1.2M | 1.61M | 786K | 57K | 1.99M | 2.22M | 2.04M | 1.1M | 2.75M | 3.98M | 3.58M | 3.37M | 8.74M | 797K |
Other Working Capital | n/a | 2.76M | -7.19M | -716.33K | 2.14M | -7.09M | 6.91M | 617.98K | 2.92M | -140K | -15K | -13K | -15K | -15K | -16K | -130K | 98K |
Other Non-Cash Items | n/a | 16.35M | -7.49M | 2.77M | 4.7M | 7.17M | -6.27M | 4.17M | 3.87M | 11.11M | -17.62M | -17.96M | 383K | 348K | -32K | 11K | 8.41M |
Deferred Income Tax | -22K | 3.19K | 1.69M | -7.03K | -36.98K | -821K | -602K | -1.14M | -516K | -1.93M | -625K | -915K | -863K | -57K | -30K | -7K | -25K |
Change in Working Capital | n/a | 15.21M | -8.8M | 1.46M | 1.28M | -10.88M | 8.26M | 542K | 8.25M | -2.57M | 19.62M | -8.95M | -13.62M | 3.01M | -845K | -7.48M | -1.86M |
Operating Cash Flow | -14.9M | 13.26M | -13.88M | -12.02M | -11.82M | -19.6M | -11.19M | -16.96M | -3.17M | -11.34M | 11.88M | -8.39M | -6.58M | -7.97M | -2.02M | -14.62M | -7.97M |
Capital Expenditures | -5K | -275.62K | 2.44M | -192.33K | -307.82K | 153K | -36K | -3.02M | -2.51M | -586K | -2.41M | -2.05M | -1.09M | -424K | -128K | -202K | -392K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.75K | 384.01K | n/a | n/a | n/a | 465.63 | 296.22K | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | -2.56M | n/a | n/a | -5.41M | n/a | n/a | n/a | -3.75K | 3.99K | n/a | n/a | -11.77M | -465.63 | -296.22K | n/a |
Investing Cash Flow | -5K | -278K | -114K | -192.33K | -307.82K | 153K | -36K | -3.02M | -2.51M | -586K | -2.02M | -2.05M | -1.09M | -12.19M | -128K | -202K | -392K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.54K | 672.56 | n/a | -159K | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2K | n/a | 465K | n/a | n/a | n/a | n/a | -63K | -84.68K | 1.54K | n/a | 53.47 | n/a | 296K | -1.74M | -756K | -444.15K |
Financial Cash Flow | 2K | 837K | 465K | 358.56K | 502.71K | 109K | 46K | 28K | 1.69M | 484K | 672.56 | 53.47 | -159K | 9K | -1.39M | 102.31M | 121.81M |
Net Cash Flow | -11.82M | 6.3M | -11.67M | -12.2M | -12.12M | -18.22M | -12.72M | -18.3M | -3.06M | -5.72M | 7.78M | -8.27M | -13.46M | -19.82M | -9.75M | 87.68M | 112.67M |
Free Cash Flow | -14.91M | 12.81M | -11.43M | -12.21M | -12.12M | -19.45M | -11.23M | -19.98M | -5.68M | -11.93M | 9.48M | -10.45M | -7.67M | -8.4M | -2.15M | -14.83M | -8.36M |